- £4.97bn
- £4.72bn
- $5.25bn
- 37
- 85
- 100
- 89
2019 December 31st | 2020 December 31st | 2021 December 31st | C2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Total Premiums Earned | |||||
Net Investment Income | |||||
Realized & Unrealized Gains / Losses | |||||
Other Revenue | |||||
Total Revenue | 2,637 | 2,911 | 3,292 | 4,871 | 5,247 |
Losses, Benefits, and Adjustments | |||||
Amortization of Policy Acquisition Costs | |||||
Selling / General / Administrative Expenses | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 2,369 | 2,962 | 2,923 | 4,288 | 3,995 |
Operating Profit | 268 | -50.4 | 369 | 584 | 1,252 |
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 268 | -50.4 | 369 | 584 | 1,254 |
Provision for Income Taxes | |||||
Net Income After Taxes | 234 | -46.5 | 308 | 482 | 1,034 |
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | 234 | -46.1 | 309 | 483 | 1,027 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Dilution Adjustment | |||||
Diluted Net Income | 234 | -46.1 | 309 | 483 | 1,027 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 0.441 | -0.08 | 0.423 | 0.778 | 1.52 |
Dividends per Share |